Furthermore, JAK1 and JAK2 inactivation has been observed in high tumor mutational burden colon cancers that were non-responsive to anti-PD1 therapy, suggesting the role IFN-y plays in anti-PD1 resistance (139). Here, PDCD1 is linked to neoplasm.